<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373058</url>
  </required_header>
  <id_info>
    <org_study_id>HIPEC-03</org_study_id>
    <nct_id>NCT03373058</nct_id>
  </id_info>
  <brief_title>Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery</brief_title>
  <acronym>EHTASEOCCS</acronym>
  <official_title>A Phase III Multicenter Prospective Randomized Controlled Clinical Trial of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Guizhou Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Second University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Obstetrics &amp; Gynecology Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fourth Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Obstetrics and Gynecology Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing University Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Shantou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is a multi-center, prospective, randomized controlled clinical observation the
      safety and efficacy of hyperthermic intraperitoneal chemotherapy in the treatment of
      advanced-stage epithelial ovarian cancer after cytoreductive surgery. Median recurrence-free
      survival is the primary end points of this project.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current standard treatment for epithelial ovarian cancer, tubal cancer, and primary
      peritoneal cancer is maximal cytoreductive surgery followed by intravenous chemotherapy with
      or without intraperitoneal chemotherapy (IP). Recently, the organizations of SGO and ASCO
      recommended that women with Fagotti score by laparoscopic exploration &lt; 6 would benefit from
      primary cytoreductive surgery followed by postoperative chemotherapy, and are likely to
      attain optimal cytoreduction (residual lesion ≤ 1 cm).

      Hyperthermia promotes chemotherapy to penetrate deeper into the cancer tissue. Therefore,
      hyperthermic intraperitoneal chemotherapy (HIPEC) as newly postoperative chemotherapy after
      primary cytoreductive surgery in the treatment of ovarian cancer could lead to higher
      response rate and better survival outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median recurrence-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>assess median recurrence-free survival during 3 years in both study arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>assess median overall survival during 3 years in both study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>assess median progression-free survival during 3 years in both study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for morbidity and mortality</measure>
    <time_frame>30 days; 3 years</time_frame>
    <description>The early complication and mortality are defined as the event observed within 30 days after intervention, while the time frame for late complication is the period beyond 30 days after intervention to the end of 3 years. Complications are ranked from grade 0-5 according to CTCAE V4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life for ovarian cancer</measure>
    <time_frame>3 years</time_frame>
    <description>Evaluated according to European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Ovarian Cancer Module (QLQ-OV28)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytoreductive surgery
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Docetaxel 75 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession
6 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV&gt;3 hour(Docetaxel 75 mg/m^2, if paclitaxel is not available.)+ carboplatin AUC = 5-6 IV&gt;1 hour, every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cytoreductive surgery
6 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV&gt;3 hour(Docetaxel 75 mg/m^2, if paclitaxel is not available)+ carboplatin AUC = 5-6 IV&gt;1 hour, every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperthermic Intraperitoneal Chemotherapy</intervention_name>
    <description>HIPEC is performed as postoperative chemotherapy after cytoreductive surgery for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 48h after cytoreductive surgery: Paclitaxel 175 mg/m^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The HIPEC regimens are Docetaxel 75 mg/m^2 and cisplatin 75 mg/m^2, respectively, 43°C, 90min.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>HIPEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cytoreductive surgery</intervention_name>
    <description>Cytoreductive surgery (CRS) is performed when Faggoti value is less than 6 via laparoscopic exploration.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>CRS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adjuvant chemotherapy</intervention_name>
    <description>Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m^2 IV&gt;3 hour+ carboplatin AUC = 5-6 IV&gt;1 hour, every 3 weeks for 2 cycles in experimental group.
Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m^2 IV&gt;3 hour+ carboplatin AUC = 5-6 IV&gt;1 hour, every 3 weeks for 3 cycles in control group.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>ACT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Disease status primary epithelial ovarian cancer, tubal cancer, and primary peritoneal
             cancer (Stage III )

          -  Fagotti score by laparoscopic exploration &lt; 6

          -  Residual tumor &lt; 1cm after completion of cytoreductive surgery

          -  18 &lt; Age &lt; 70 year old

          -  Expected survival &gt; 3 months

          -  Performance status: ECOG 0-1

          -  Adequate bone marrow function Hb ≥8 g/dl (After correction in case of iron deficient
             anemia) WBC ≥ 3,000/mm3, Platelet ≥ 100,000/mm3

          -  Adequate renal function Creatinine ≤ 1.5 mg/dl, and adequate hepatic function
             Bilirubin ≤ 1.5 mg/dl and AST and ALT ≤ 80 IU/L

          -  Voluntary participation after getting written informed consent.

        Exclusion Criteria:

          -  Fagotti score by laparoscopic exploration &gt;= 6

          -  Suboptimal debulking (residual tumor &gt; 1cm)

          -  Extensive adhesion in peritoneal cavity

          -  Previous History of other malignancies (except excision of skin cancer, thyroid
             cancer)

          -  Poorly controlled disease e.g. atrial fibrillation, stenocardia, cardiac
             insufficiency, persistent hypertension despite medicinal treatment, ejection
             fraction&lt;50%

          -  Receiving other chemotherapy, radiotherapy or immunotherapy

          -  Patients who are unsuitable candidates by doctor's decision

          -  Without given written informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuzhong Cui, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhongqiu Lin, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen Memorial Hospital,Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuzhong Cui, M.D</last_name>
    <phone>0086-138-0251-3800</phone>
    <email>cuishuzhong@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xian-Zi Yang, M.D</last_name>
    <phone>0086-188-9853-4167</phone>
    <email>7097359@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Affiliated Tumor Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510095</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shuzhong cui, M.D</last_name>
      <phone>0086-138-0251-3800</phone>
      <email>cuishuzhong@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhen Tang, M.M</last_name>
      <phone>0086-159-2081-9128</phone>
      <email>57932181@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>shuzhong cui, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital,Sun Yat-sen University</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <zip>510235</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongqiu Lin, MD</last_name>
      <phone>08613802921545</phone>
      <email>lin-zhongqiu@163.com</email>
    </contact>
    <investigator>
      <last_name>Jing Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunong Gao, MD</last_name>
      <phone>010-88196216</phone>
    </contact>
    <investigator>
      <last_name>Qian Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Zhou, MD</last_name>
      <email>qizhou9128@163.com</email>
    </contact>
    <investigator>
      <last_name>Xingtao Long, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junying Tang, MD</last_name>
      <email>tangjy_cqmu@sina.com</email>
    </contact>
    <investigator>
      <last_name>Lin Xiao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hubei General Hospital</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LI Hong, MD</last_name>
      <email>1072247562@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Wang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 4, 2017</study_first_submitted>
  <study_first_submitted_qc>December 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperthermic Intraperitoneal Chemotherapy</keyword>
  <keyword>Advanced-Stage Epithelial Ovarian Cancer</keyword>
  <keyword>Cytoreductive surgery</keyword>
  <keyword>Postoperative Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

